DRAFT PROGRAMME
Enacting sustainable system-wide change to cardiovascular care

09:00 - 09:05

Chair’s Opening Remarks
Alastair McLellan,
Editor, HSJ

09:05 - 09:35

Assessing the impact of COVID-19 on national stroke and cardiovascular plans

  • Responding to the pandemic and taking forward learning on admissions and service provision
  • Understand the longer term effects for cardiovascular care delivery in the NHS
  • How the NHS can get back on track with delivering the long term plan following COVID-19
  • Identify how to ensure that change is sustainable, including supporting and building a competent and confident workforce

Dr Sarah Clarke, Joint Clinical Lead, Cardiology, GIRFT

Professor Gary Ford, Chief Executive Officer, Oxford Academic Health Science Network

Dr Raj Thakkar, GP, Bourne End and Wooburn Green Medical Centre, Bucks, Clinical Commissioning Director,
Planned Care, Bucks CCG, Cardiac lead, Oxford AHSN and LTC lead for TV SCN, NHS England

09:35 - 09:45

Live Q&A

09:45 - 10:00

Short break and session change

10:00 - 10:30

CVDPrevent: Driving change in the context of COVID-19

  • Understand how to use the data from the national primary care audit to identify how many of the six high risk conditions are potentially undiagnosed, undertreated or overtreated
  • Hear tangible examples of how the information from the audit can drive change and underpin prevention work and ultimately address gaps in outcomes
  • Learn about a framework being developed by UCLPartners to support PCNs and primary care to do things differently post-covid, including remote monitoring and proactive management for CVD

Dr Matt Kearney, Programme Director, UCLPartners AHSN, National Clinical Lead for CVD Prevention, Public Health England and GP in Shropshire



Lorraine Oldridge, National Lead – National Cardiovascular Intelligence Network (NCVIN), Public Health England

(Session in association with Bayer)

10:30 - 10:40

Live Q&A

10:40 - 11:10

Short break and session change

11:10 - 11:40

Creating a sustainable, whole system approach to CVD prevention

  • Identify the enabling factors to ensure change happens and is sustainable
  • Activate and involve all stakeholders to work towards preventing 150,000 heart attacks, strokes and dementia cases
  • Build a workforce that is competent, confident and enthused to continue CVD prevention work at scale and beyond pilots
11:40 - 11:50

Live Q&A

11:50 - 12:05

Short break and session change

12:05 - 12:35

Overcoming the challenges of managing cardiometabolic disease

  • Examine the cardiometabolic pathway in the context of COVID-19
  • Address the cardiovascular risk for those with diabetes
  • Discuss a blueprint for putting together a cardiometabolic pathway

Professor Wasim Hanif, Professor of Diabetes & Endocrinology, Consultant Physician & Head of Service,
University Hospital Birmingham

Professor Partha Kar, National Specialty Advisor, Diabetes, NHS England and GIRFT Co-lead, Diabetes, NHS
Improvement (Invited)

(Session in association with Boehringer Ingelheim)

12:35 - 12:50

Live Q&A and Chair’s Closing Remarks

End of live sessions

Download the programme here.

Registration
Medical directors and associate medical directors; Clinical directors and consultant cardiologists from secondary providers; Clinical chairs and directors of commissioning from CCGs; Clinical leads and clinical directors from STPs/ICSs; Executive directors and clinical leads from GP Federations and Primary Care Networks; GPs, community pharmacists, community nurses and practice nurses; Very senior managers from arms’ length bodies including NHS England and NHS Improvement; Leaders in public health from local authorities - register your free place here.

Partnership Enquiries
Please contact Brett Mitchell to understand how you can be part of the Forum or download our brochure here.

Copyright© 2020 Wilmington plc
This programme is a draft, Health Service Journal, part of Wilmington plc, reserves the right to alter the venue and/or speakers at any time.

Wilmington/ HSJ are pleased to have worked with Bayer on the development of the agenda. Bayer has provided funding for this meeting and is sponsoring presentations clearly outlined in the programme. A Bayer employee will be delivering a presentation at this meeting.